Publicaciones en colaboración con investigadores/as de Claude Bernard University Lyon 1 (36)

2024

  1. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

    European Journal of Cancer, Vol. 202

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

2023

  1. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

    Frontiers in Medicine, Vol. 10

  2. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Cancers, Vol. 15, Núm. 13

  3. GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

    Cell Reports Medicine, Vol. 4, Núm. 12

  4. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 34, Núm. 10, pp. 833-848

  5. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  2. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

    Gynecologic Oncology, Vol. 164, Núm. 2, pp. 254-264

  3. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Annals of Oncology, Vol. 33, Núm. 3, pp. 276-287

  4. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 174, pp. 221-231

2021

  1. Bringing onco‐innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

    Cancers, Vol. 13, Núm. 3, pp. 1-12

  2. Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))

    Annals of Oncology

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Maintenance treatment of newly diagnosed advanced ovarian cancer: Time for a paradigm shift?

    Cancers, Vol. 13, Núm. 22

  5. Managing recurrent ovarian cancer in daily clinical practice: Case studies and evidence review with a focus on the use of trabectedin

    Future Oncology, Vol. 17, Núm. 3s, pp. 9-19

  6. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

    The Lancet Haematology, Vol. 8, Núm. 2, pp. e122-e134

  7. The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas

    Cancer Treatment Reviews, Vol. 100

2020

  1. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners -a new Model D for drug and medical device development

    International Journal of Gynecological Cancer, Vol. 30, Núm. 6, pp. 730-734

  2. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    International Journal of Cancer, Vol. 146, Núm. 2, pp. 439-448